Literature DB >> 8587068

What explains the variation among rheumatologists in their use of prednisone and second line agents for the treatment of rheumatoid arthritis?

L A Criswell1, C J Henke.   

Abstract

OBJECTIVE: To determine the extent to which characteristics of rheumatologists and their practices explain the variation in their use of prednisone and 2nd line agents for the treatment of rheumatoid arthritis (RA).
METHODS: We used multiple logistic regression to examine the relationship between the use of prednisone, hydroxychloroquine, intramuscular gold, and methotrexate, and the following categories of rheumatologist characteristics: professional experience, primary payment method, practice setting, location of rheumatology training, and demographic characteristics. Our explanatory variables also included 12 patient characteristics and a random effect term.
RESULTS: Much of the variation among rheumatologists in the use of these agents is explained by the rheumatologist characteristics. Depending on the agent, professional experience explained 15 to 54%, payment method 3 to 27%, practice setting 6 to 39%, training location 12 to 53%, and demographic characteristics 3 to 23% of the rheumatologist associated variation in use of each agent.
CONCLUSION: There are identifiable characteristics of rheumatologists and their practices that strongly influence their treatment decisions for RA. These findings have important policy implications.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8587068

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  9 in total

1.  Synthetic disease-modifying antirheumatic drug prescribing variability in rheumatoid arthritis: a multilevel analysis of a cross-sectional national study.

Authors:  Iván Ferraz-Amaro; Daniel Seoane-Mato; Fernando Sánchez-Alonso; María A Martín-Martínez
Journal:  Rheumatol Int       Date:  2015-09-24       Impact factor: 2.631

2.  Patient centred outcomes in osteoarthritis.

Authors:  J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2005-01       Impact factor: 19.103

3.  Trends in disease modifying antirheumatic drug prescription in early rheumatoid arthritis are influenced more by hospital setting than patient or disease characteristics.

Authors:  C Carli; A G C Ehlin; L Klareskog; S Lindblad; S M Montgomery
Journal:  Ann Rheum Dis       Date:  2005-12-01       Impact factor: 19.103

4.  The art versus the science of medicine. Are clinical practice guidelines the answer?

Authors:  M E Suarez-Almazor; A S Russell
Journal:  Ann Rheum Dis       Date:  1998-02       Impact factor: 19.103

5.  A maximum difference scaling survey of barriers to intensive combination treatment strategies with glucocorticoids in early rheumatoid arthritis.

Authors:  Sabrina Meyfroidt; Marlies Hulscher; Diederik De Cock; Kristien Van der Elst; Johan Joly; René Westhovens; Patrick Verschueren
Journal:  Clin Rheumatol       Date:  2015-02-26       Impact factor: 2.980

6.  The national database of the German Collaborative Arthritis Centres: II. Treatment of patients with rheumatoid arthritis.

Authors:  A Zink; J Listing; M Niewerth; H Zeidler
Journal:  Ann Rheum Dis       Date:  2001-03       Impact factor: 19.103

7.  Time trends in glucocorticoid use in rheumatoid arthritis: results from a population-based inception cohort, 1980-1994 versus 1995-2007.

Authors:  Ashima Makol; John M Davis; Cynthia S Crowson; Terry M Therneau; Sherine E Gabriel; Eric L Matteson
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-10       Impact factor: 4.794

8.  Patterns of glucocorticoid prescribing and provider-level variation in a commercially insured incident rheumatoid arthritis population: A retrospective cohort study.

Authors:  Beth I Wallace; Paul Lin; Neil Kamdar; Mohamed Noureldin; Rodney Hayward; David A Fox; Jeffrey R Curtis; Kenneth G Saag; Akbar K Waljee
Journal:  Semin Arthritis Rheum       Date:  2019-09-07       Impact factor: 5.532

9.  Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative.

Authors:  K Visser; W Katchamart; E Loza; J A Martinez-Lopez; C Salliot; J Trudeau; C Bombardier; L Carmona; D van der Heijde; J W J Bijlsma; D T Boumpas; H Canhao; C J Edwards; V Hamuryudan; T K Kvien; B F Leeb; E M Martín-Mola; H Mielants; U Müller-Ladner; G Murphy; M Østergaard; I A Pereira; C Ramos-Remus; G Valentini; J Zochling; M Dougados
Journal:  Ann Rheum Dis       Date:  2008-11-25       Impact factor: 19.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.